Company intelligence / Profile preview
Ceria Therapeutics, Inc.
- Ownership
- Private
- Development stage
- Preclinical
Overview
Ceria Therapeutics is a preclinical-stage biotech company developing first-in-class drug products that target the root cause of inflammation in acute and chronic conditions. Their lead programs use nanoparticle-based delivery of miR146a to modulate inflammatory pathways. The company has received multiple SBIR grants and a Department of Defense contract to advance its pipeline toward IND-enabling studies for indications such as acute lung injury and non-healing diabetic foot ulcers. No clinical results are available yet as all programs remain preclinical.
- Therapeutic areas
- PulmonologyEndocrinologyDermatologyGastroenterologyNephrologyInfectious Diseases
- Modalities
- microRNA therapeutics (miRNA)Nanoparticle drug delivery
- Industry
- Biotech
Drug pipeline
9 assets8 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Ceria Therapeutics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ceria Therapeutics, Inc..